ARS Pharma Sales Jump 3,040% in Q2
ARS Pharmaceuticals (NASDAQ:SPRY), the biopharma company developing needle-free allergy treatments, released its second-quarter 2025 results on August 13, 2025. The most significant takeaway from the release was a major GAAP revenue beat, as total GAAP revenue climbed to $15.7 million versus the $13.8 million analyst expectation (GAAP). neffy, its epinephrine nasal spray, drove this revenue, with prescription volume and market coverage both expanding sharply. On the other hand, Elevated spending, especially on sales and marketing, led to a net loss per share of $(0.46) (GAAP). The quarter was defined by accelerating product momentum offset by persistent, high operating costs as commercialization activities scaled up.
Source: ARS Pharmaceuticals. Note: Analyst estimates provided by FactSet.
ARS Pharmaceuticals specializes in developing and commercializing treatments for severe allergic reactions. Its flagship product, neffy, is a needle-free epinephrine nasal spray approved for emergency use in patients with type I allergic reactions, including anaphylaxis. The U.S. epinephrine market has historically relied on injectors, like EpiPen, which many patients find difficult or intimidating to use.
Source Fool.com
